The picks-and-shovels play on nuclear
Of the six names in Karim Rahemtulla’s Energy Cube sleeve, Mirion Technologies (MIR) is the one closest to a pure infrastructure play. It does not build reactors and it does not mine uranium. It makes the radiation-monitoring and measurement equipment that every nuclear facility, old or new, has to buy and maintain.
What Mirion does
Mirion sells radiation detection, measurement, and monitoring systems used across nuclear power, medical imaging, and defense. In the nuclear context, that means the dosimeters, detectors, and monitoring systems that keep a plant compliant with safety regulations and keep its workers safe. The business is less glamorous than a reactor developer, and that is exactly the point: it is a recurring, regulated line of demand rather than a single bet on one reactor design winning.
The roughly 95% moat
The number the pitch leans on is that roughly 95% of the world’s commercial nuclear plants use Mirion’s monitoring equipment. That level of installed base is a genuine regulatory moat, because nuclear operators do not casually swap out safety instrumentation. New plants, whether conventional or small modular, have to install monitoring from the start, and existing plants have to keep it current. That makes Mirion a picks-and-shovels way to play the entire nuclear buildout without betting on which reactor technology prevails.
Why the moat matters for SMRs
This is the part that connects Mirion to the Energy Cube thesis. The small modular reactor story is a decade-scale bet on a specific new technology, and a lot of the value depends on designs clearing regulators and utilities ordering units. Mirion’s monitoring gear is needed on a reactor regardless of whether it is a 470-megawatt Rolls-Royce design or a conventional plant. If the SMR buildout stalls, Mirion still sells into the existing nuclear fleet and its medical and defense markets.
The other half of the business
The moat is not only about nuclear power. Mirion also supplies radiation measurement to the medical-imaging and defense markets, which means its revenue does not live or die on a single reactor cycle. That diversification is part of why the company earns real revenue today, rather than waiting on the 2030s, and it is the structural difference between Mirion and a pure reactor developer. It also means the stock is never a pure bet on the nuclear buildout, which cuts both ways: smoother through a reactor-cycle pause, but slower to re-rate on a uranium spike.
The price since the tease
Mirion traded around $17.91 when the tease price was set and closed near $15.59 on September 25, down about 13%. That places it among the four Energy Cube names underwater since the tease, and it is worth remembering that a moat is a long-term asset, not a shield against a short-term selloff.
The regulatory angle that protects the moat
The reason roughly 95% market share sticks is regulation. Nuclear safety monitoring is not equipment an operator chooses freely; it is equipment a regulator effectively requires, and changing vendors means re-validating instruments against licensing conditions. That switching cost is the moat’s real foundation, and it is why Mirion’s position does not depend on winning any particular reactor contract. Every new plant, conventional or small modular, has to install monitoring before it can operate, and every existing plant has to maintain and refresh its instruments to stay licensed.
There is a tradeoff inside that protection. A business that is hard to dislodge is also hard to accelerate; Mirion grows with the installed base and the new-build pipeline rather than in sudden leaps. That is the honest character of the stock: a steady compounder with a defensible niche, not a tenfold lottery ticket. For an investor who wants nuclear exposure without betting on a single reactor design, that is exactly the profile that fits. Monitoring equipment is the picks-and-shovels of the nuclear buildout, and the historical record is that picks-and-shovels businesses survive cycles better than the miners and builders they supply. Mirion does not need the uranium price to rise or a reactor design to win; it needs plants to keep running and new plants to keep getting licensed, and both of those are already happening.
How to think about Mirion
Mirion is the most defensive way to express a nuclear view inside this sleeve. It has real revenue today, a defensible installed base, and exposure to whatever the reactor market becomes. We place it in the reactor value chain in our nuclear reactor companies walkthrough, and rank it against the field in our best nuclear stocks piece. The reactor programs it would serve are covered in our small modular reactor stocks explainer.
The honest read: Mirion is a real moat wrapped in a hype-heavy pitch, and the moat survives even if the pitch’s urgency does not.
Ready to see the research? Click here to access Karim Rahemtulla’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.